Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05803941
Phase: PHASE4
Trial Summary: The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 17 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Novartis Pharmaceuticals
Acronym:

Pin It on Pinterest